MktsMarkets

GT Biopharma, Inc.
NASDAQ: GTBPKey statistics
GTBP News
Stories mentioning GTBP from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 413.00 | 1,376 | 634.00 | 363.00 | 1,099 | 1,930 | 1,307 | 1,784 |
| Sales General & Admin | 2,435 | 4,219 | 2,748 | 1,150 | 833.00 | 1,833 | 2,297 | 2,122 |
| Total Operating Expenses | 1,987 | 488.00 | ||||||
| Operating Income (Loss) | (2,848) | (5,595) | (3,382) | (1,513) | (1,932) | (3,763) | (3,604) | (3,906) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 156.00 | (27.00) | ||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (2,833) | (5,708) | 8,299 | (30,169) | (776.00) | (3,775) | (3,411) | (3,710) |
| Earnings Per Share (Basic) | (0.11) | (1.04) | 1.04 | (10.92) | (0.33) | (1.99) | (1.53) | (2.17) |
| Earnings Per Share (Diluted) | (0.11) | (1.04) | 1.04 | (10.92) | (0.33) | (1.99) | (1.53) | (2.17) |
| Weighted Average Shares Outstanding (Basic) | 30,283 | 5,513 | 3,941 | 2,772 | 2,345 | 1,897 | 2,234 | 1,712 |
| Weighted Average Shares Outstanding (Diluted) | 30,283 | 5,513 | 3,941 | 2,772 | 2,345 | 1,897 | 2,234 | 1,712 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About GTBP
GT Biopharma, Inc. (NASDAQ: GTBP) is a stock listed on the Nasdaq Stock Market under the ticker symbol GTBP. It last traded at $3.97 (Nov 11, 2026, 2:18 PM ET), up 0.3% on the day. That gives GT Biopharma a market capitalisation of $8.2M.
Over the past 52 weeks GTBP has traded between $4.21 and $28.75.
For the quarter ended Mar 31, 2026 it reported a net loss of $2.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$2.8M |
| Dec 31, 2025 | — | -$5.7M |
| Sep 30, 2025 | — | $8.3M |
| Jun 30, 2025 | — | -$30.2M |
From GT Biopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…